AngloGold Ashanti (NYSE:AU,JSE:ANG)said on Monday (March 31) that with the completion of its Tropicana renewables project it has created the largest hybrid power system in Australia’s mining sector.
First introduced by AngloGold in June 2023, the renewables project is a partnership with Pacific Energy (ASX:PEA), which will integrate 61 megawatts of wind and solar generation capacity at the Tropicana development.
Tropicana is located in Western Australia roughly 1,000 kilometres east of Perth and is a joint venture between AngloGold and fellow gold producer Regis Resources (ASX:RRL,OTC Pink:RGRNF).
The former holds a 70 percent interest in the project, while the latter owns the remaining 30 percent.
The renewables project is expected to reduce the Tropicana development’s natural gas consumption by approximately 50 percent and decrease carbon emissions by an average of 65,000 tonnes annually over the next decade. The project was completed on time, as construction began toward the end of 2023 and was expected to finish during Q1 2025.
“This project will enable a significant reduction in emissions while reducing both diesel and natural gas consumption and improving our overall security of energy supply,” said AngloGold CEO Alberto Calderon.
The project’s energy capacity is equivalent to powering between 40,000 and 50,000 average Australian homes annually. AngloGold believes Tropicana enhances its net asset value, underlining its status as a valuable investment.
In the long run, the renewables initiative will play a crucial role in AngloGold’s 2030 decarbonisation goal, which calls for a 30 percent reduction in Scope 1 and 2 greenhouse gas emissions based on its 2021 carbon emissions baseline.
Outlining the project’s environmental impact in a fact sheet, AngloGold compares it to planting 33 million trees annually, removing 23,000 cars from the road each year or eliminating 2.8 million long-haul flights per year.
Additionally, the plant is expected to reduce the Tropicana operation’s diesel consumption by 5.6 million litres annually and cut natural gas usage by 1.1 million gigajoules per year.
Pacific Energy was responsible for designing and constructing the expansion. The company also owns and operates the hybrid renewables-natural gas power station under a 10 year power purchase agreement.
Combined, the thermal and renewable power systems will provide a total capacity of 115 megawatts.
Securities Disclosure: I, Gabrielle de la Cruz, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
WASHINGTON — Boeing CEO Kelly Ortberg told senators on Wednesday that he’s happy with the company’s progress improving manufacturing and safety practices following several accidents, including a near catastrophe last year.
Ortberg faced questioning from the Senate Commerce Committee about how the company will ensure that it doesn’t repeat past accidents or manufacturing defects, in his first hearing since he became CEO last August, tasked with turning the manufacturer around.
Sen. Ted Cruz, R.-Texas, the committee’s chairman, said he wants Boeing to succeed and invited company managers and factory workers to report to him their opinions on its turnaround plan. “Consider my door open,” he said.
Ortberg acknowledged the company still has more to do.
“Boeing has made serious missteps in recent years — and it is unacceptable. In response, we have made sweeping changes to the people, processes, and overall structure of our company,” Ortberg said in his testimony. “While there is still work ahead of us, these profound changes are underpinned by the deep commitment from all of us to the safety of our products and services.”
Boeing executives have worked for years to put the lasting impact of two fatal crashes of its best-selling Max plane behind it.
Ortberg said Boeing is in discussions with the Justice Department for a revised plea agreement stemming from a federal fraud charge in the development of Boeing’s best-selling 737 Maxes. The previous plea deal, reached last July, was later rejected by a federal judge, who last month set a trial date for June 23 if a new deal isn’t reached.
Boeing had agreed to plead guilty to conspiring to defraud the U.S. government, pay up to $487.2 million and install a corporate monitor at the company for three years.
“We’re in the process right now of going back with the DOJ and coming up with an alternate agreement,” Ortberg said during the hearing. “I want this resolved as fast as anybody. We’re still in discussions and hopefully we’ll have a new agreement here soon.”
Asked by Sen. Maria Cantwell, the ranking Democrat on the committee, whether he had an issue with having a corporate monitor, Ortberg replied: “I don’t personally have a problem, no.”
Ortberg and other Boeing executives have recently outlined improvements across the manufacturer’s production lines, such as reducing defects and risks from so-called traveled works, or doing tasks out of sequence, in recent months, as well as wins like a contract worth more than $20 billion to build the United States’ next generation fighter jet.
But lawmakers and regulators have maintained heightened scrutiny on the company, a top U.S. exporter.
“Boeing has been a great American manufacturer and all of us should want to see it thrive,” Sen. Ted Cruz, a Texas Republican and chairman of the committee, said in a statement in February announcing the hearing. “Given Boeing’s past missteps and problems, the flying public deserves to hear what changes are being made to rehabilitate the company’s tarnished reputation.”
The Federal Aviation Administration last year capped Boeing’s production of its 737 Max planes at 38 a month following the January 2024 door plug blowout. The agency plans to keep that limit in place, though Boeing is producing below that level.
Ortberg said at the hearing Wednesday that the company could work up to production rate of 38 Max planes a month or even higher sometime this year, but said Boeing wouldn’t push it if the production line isn’t stable.
Acting FAA Administrator Chris Rocheleau said at a Senate hearing last week that the agency’s oversight of the company “extends to ongoing monitoring of Boeing’s manufacturing practices, maintenance procedures, and software updates.”
This post appeared first on NBC NEWS
This post appeared first on FOX NEWS
Val Kilmer, the acclaimed actor behind iconic roles in Top Gun, Batman Forever, and The Doors, has died at the age of 65.
He passed away on Tuesday night in Los Angeles from pneumonia, according to his daughter Mercedes Kilmer.
Despite a battle with throat cancer diagnosed in 2014, Kilmer had recovered after multiple tracheotomies and extensive treatment.
Although Kilmer’s on-screen legacy spans decades, his financial story reflects a dramatic shift from one of Hollywood’s highest-paid stars in the 1990s to a more modest net worth in later years.
At the time of his death in 2025, his fortune was reportedly estimated at $10 million.
Kilmer’s peak Hollywood earnings
Val Kilmer’s career reached its financial zenith in the mid-’90s.
In 1995, he earned $7 million for Batman Forever — equivalent to about $12 million today — making him one of the top-paid actors of the era.
This was followed by a $7 million paycheque for The Saint and $6 million for The Island of Dr. Moreau in 1997, totalling $13 million in that year alone.
His highest single payday came in 1999 when he received $9 million for At First Sight.
These multi-million-dollar contracts made him a regular fixture on studio shortlists for blockbuster leads, with his intense method acting style and versatile performances often drawing both praise and friction on set.
Property, books, and royalties
Although Kilmer faced financial challenges later in life, including the cost of health treatments and the impact of a high-profile divorce, his wealth remained supported by a range of creative and business pursuits.
He previously owned a 6,000-acre ranch in New Mexico, which he began selling in parts in 2009.
By 2011, most of the property had been sold for $18.5 million, though he retained 160 acres until his death.
Kilmer also turned to writing, publishing I’m Your Huckleberry: A Memoir, which became a New York Times bestseller.
He had earlier released poetry collections and, in 2012, earned a Grammy nomination for his spoken word album The Mark of Zorro.
These projects, along with residuals from past roles, contributed to his $10 million net worth by 2025.
Health battles and final roles
Val Kilmer’s career slowed in the 2000s after back-to-back commercial failures such as Red Planet.
He transitioned to indie films and stage productions, including a one-man show, Citizen Twain, in 2012.
In 2017, he appeared in Terrence Malick’s Song to Song, and in 2022, he made a brief return as Iceman in Top Gun: Maverick, reportedly earning $400,000 for the cameo, though the figure was never confirmed.
Despite his limited speaking ability following trachea surgeries, his performance in Top Gun: Maverick received attention for its emotional resonance.
The film marked a significant public return and introduced Kilmer to a new generation of viewers.
Method acting and controversy
Known for his commitment to roles, Kilmer trained under the Suzuki Method and often stayed in character off-camera.
While filming Tombstone, he reportedly filled his bed with ice to mimic the symptoms of tuberculosis.
For The Doors, he wore leather pants year-round and insisted on being called Jim Morrison by the cast and crew.
These intense preparations, however, earned him a reputation for being difficult on set.
Filmmakers such as Joel Schumacher and John Frankenheimer publicly criticised his behaviour, though others like Irwin Winkler acknowledged his talent and creative input.
Kilmer acknowledged the friction in his 2021 documentary Val, stating that his dedication to artistic truth sometimes alienated studio heads.
In his memoir, he noted, “I had been deemed difficult and alienated the head of every major studio.”
His political activity included supporting Ralph Nader’s 2008 campaign and advocating for religious exemptions to Obamacare in 2013.
In 2009, he considered running for governor of New Mexico, where he lived.
Val Kilmer is survived by his children, Mercedes and Jack Kilmer.
The post Val Kilmer dies at 65 in Los Angeles, leaving behind $10 million fortune appeared first on Invezz
The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is still trading at three-year highs, despite current market volatility, in response to breakthrough innovations and increased deals involving biotech stocks listed on the NASDAQ.
After dropping to a low of 3,637.05 in October 2023, the index climbed to a nearly three year peak of 4,954.813 on September 19, 2024. While the index had pulled back to 4,243.7 as of March 31, 2025, further growth could be in store in the future.
According to a Towards Healthcare analyst report, the global biotech market is expected to grow at a compound annual growth rate of 12.5 percent from now to 2034, reaching a valuation of US$5.036 trillion.
Driving that growth will be favorable government policies, investment in the sector, increased demand for synthetic biology and a rise in chronic disorders such as cancer, heart disease and hypertension.
The top NASDAQ biotech stocks have seen sizeable share price increases over the past year. For those interested in investing in biotech companies, the best-performing small-cap biotech stocks are outlined below.
Data was gathered on March 31, 2025, using TradingView’s stock screener. Small-cap biotech stocks with market caps between US$50 million and US$500 million at that time were considered for this list.
1. Bright Minds Biosciences (NASDAQ:DRUG)
Company Profile
Year-over-year gain: 2,942.02 percent
Market cap: US$254.99 million
Share price: US$36.20
Bright Minds Biosciences is developing novel treatments for pain and neuropsychiatric disorders such as epilepsy, post-traumatic stress disorder and difficult-to-treat depression.The company’s platform includes serotonin agonists designed to provide powerful therapeutic benefits while minimizing side effects.
Bright Minds is currently in Phase 2 clinical trials for BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with classic absence epilepsy and developmental epileptic encephalopathy.
Bright Minds’ share price rocketed upward in the fourth quarter of last year, shooting up from US$2.49 to US$38.49 in one day on October 15. The company issued a press release at the time, stating it was ‘unaware of any material changes in the company’s operations’ that would have contributed to such a rally.
The outperformance appears to be related to the October 14 news that Danish pharma company H. Lundbeck was to acquire Longboard Pharma, a company developing a 5-HT2C receptor agonist, for US$60 per share.
A few days later, Bright Minds announced a non-brokered private placement of US$35 million, which sent shares up to US$47.21 on October 18.
That same month, the company shared its collaboration with Firefly Neuroscience (NASDAQ:AIFF) to use Firefly’s Brain Network Analytics technology platform to provide a full analysis of the electroencephalogram data from Bright Minds’ BMB-101 Phase 2 clinical trial. This follows the pair’s previous successful collaboration to analyze data from Bright Minds’ first-in-human Phase 1 study of BMB-101.
In March 2025, Bright Minds expanded its Scientific Advisory Board with the addition of five experts in epilepsy research.
Bright Minds’ share price reached US$55.77, its peak for the past year, on November 6.
2. Monopar Therapeutics (NASDAQ:MNPR)
Company Profile
Year-over-year gain: 924.54 percent
Market cap: US$220.3 million
Share price: US$36.10
Clinical-stage biotech Monopar Therapeutics’ main drug candidate is its late-stage ALXN-1840 for Wilson disease. Its pipeline also includes radiopharma programs such as Phase 1-stage MNPR-101-Zr for imaging advanced cancers, as well as Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers.
Shares in Monopar spiked by more than 600 percent on October 24, 2024, to US$32.66 following its news release detailing its exclusive worldwide licensing agreement with Alexion, AstraZeneca’s (NASDAQ:AZN) Rare Disease unit, for ALXN-1840, a drug candidate for Wilson disease that met its primary endpoints in its Phase 3 clinical trial. Going forward, Monopar will be responsible for all future global development and commercialization activities.
Further positive news flow in December continued to drive the company’s stock value. Early in the month, the company shared that the first patient was dosed with MNPR-101-Lu in its Phase 1a trial for the radiopharmaceutical. A few weeks later, Monopar announced the launch of a US$40 million concurrent public offering and private placement. After having fallen back to the US$22 range, shares in the company climbed to US$30.68 on December 17, 2024.
Positive sentiment in the company and the biotech market would later drive the stock up to its yearly high of US$51.89 on February 10, 2025. Monopar released its Q4 and full-year 2024 results on March 31.
3. Candel Therapeutics (NASDAQ:CADL)
Company Profile
Year-over-year gain: 268.3 percent
Market cap: US$262.39 million
Share price: US$5.64
Candel Therapeutics is a biotech company focused on developing oncology treatments. The company’s pipeline includes two clinical-stage multimodal biological immunotherapy platforms.
Candel’s lead product candidate, CAN-2409, is in a Phase 2 clinical trial in non-small cell lung cancer and borderline resectable pancreatic cancer, as well as Phase 2 and 3 trials for localized, non-metastatic prostate cancer.
The company had a number wins with the US Food and Drug Administration (FDA) in 2024. In February and May, respectively, Candel’s CAN-3110 received regulatory approval for fast-track designation and orphan drug designation for the treatment of recurrent high-grade glioma.
The agency also granted Candel orphan drug designation for CAN-2409 for the treatment of pancreatic cancer in April 2024. Positive interim data for the trial on pancreatic cancer released that month, sent the company’s share price spiking upward. It ultimately climbed to its 2024 high point of US$14.00 on May 15, 2024.
So far in 2025, Candel’s share price has traded as high as US$12.21 on February 20. In its January corporate update, the company shared its goals for the year, including aiming for Q4 for reporting overall survival data in patients with recurrent high-grade glioma from its ongoing phase 1b trial that is evaluating multiple doses of CAN-3110.
4. Tiziana Life Sciences (NASDAQ:TLSA)
Company Profile
Year-over-year gain: 154.76 percent
Market cap: US$119.51 million
Share price: US$1.08
Tiziana Life Sciences is a clinical-stage biopharma which is developing therapies for autoimmune and inflammatory diseases, degenerative diseases, and cancer-related to the liver. Its pipeline of candidates is built on its patent drug delivery technology that provides a possible alternative to intravenous (IV) delivery. Tiziana’s lead candidate is intranasal foralumab, which it says is the only fully human anti-CD3 mAb currently in clinical development.
On May 31, 2024, shares in Tiziana broke above US$1 after a series of positive news flow for the company. This included positive clinical results from its intermediate sized Expanded Access Program for non-active secondary progressive multiple sclerosis patients, which demonstrated multiple improvements in foralumab-treated patients, as well as its submission of an orphan drug designation application to the FDA for intranasal foralumab for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS).
While Tiazana’s share price slid back down below US$1 per share by mid-June 2024, news that the FDA granted fast track designation to Tiziana intranasal foralumab for the treatment of na-SPMS gave it a much needed boost to the upside. By August 12, the stock’s value had risen to US$1.45 per share.
Tiziana Life Sciences shares reached a yearly peak of US$1.69 on March 7, 2025, after the company filed its investigational new drug application to the FDA for a phase 2 clinical trial in amyotrophic lateral sclerosis (ALS), which is supported by the ALS Association.
5. Benitec Biopharma (NASDAQ:BNTC)
Company Profile
Year-over-year gain: 149.71 percent
Market cap: US$331.43 million
Share price: US$13.01
California-based Benitec Biopharma is advancing novel genetic medicines via its proprietary “Silence and Replace” DNA-directed RNA interference platform. The company is currently focused on developing therapeutics for chronic and life-threatening conditions, including oculopharyngeal muscular dystrophy (OPMD).
Its drug candidate BB-301 was granted orphan drug designation by the FDA and the European Medicines Agency. Benitec is well funded to advance its BB-301 clinical development program through the end of 2025.
Benitec’s share price benefited from its first bump of the past year, after the company released its fiscal year Q3 2024 update in mid-May highlighting its achievements over the quarter. This included the closing of a US$40 million private placement. Benitec’s stock value hit US$10.47 per share on May 20, 2024.
Later in the fall, the company reported positive data from two patients with OPMD treated with low-dose BB-301 in phase 1b/2a study, showing the clinical trial is meeting key safety and efficacy endpoints. Shares hit another high of US$11.22 on October 17, 2024.
Benitec’s share price hit US$16.79, its highest yearly value to date, on March 20, 2025, a day after the company released positive interim clinical results for three patients with OPMD treated with BB-301 in phase 1b/2a study.
“The sixth and final Subject of Cohort 1 will be treated with BB-301 in the second calendar quarter of this year, and we are highly optimistic about the potential for continued benefit in Subjects enrolled in the ongoing clinical study,” said Jerel A. Banks, Benitec Executive Chairman and CEO.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
This post appeared first on investingnews.com
Restaurant chain Hooters of America filed for bankruptcy protection in Texas on Monday, seeking to address its $376 million debt by selling all of its company-owned restaurants to a franchise group backed by the company’s founders.
Hooters, like other casual dining restaurants, has struggled in recent years due to inflation, the high costs of labor and food and declining spending by cash-strapped American consumers. The company currently directly owns and operates 151 locations, with another 154 restaurants operated by franchisees, primarily in the United States.
The privately-owned company, which shares a private equity owner with recently-bankrupt TGI Fridays, intends to sell all corporate-owned locations to a buyer group comprised of two existing Hooters franchisees, who operate 30 high-performing Hooters locations in the U.S., mainly in Florida and Illinois.
Hooters did not disclose the purchase price of the transaction, which must be approved by a U.S. bankruptcy judge before it becomes final.
Founded in 1983, Hooters became famous for its chicken wings and its servers’ uniform of orange shorts and low-cut tank tops.
The buyer group is backed by some of Hooters’ original founders, and it pledged to take Hooters “back to its roots.”
“With over 30 years of hands-on experience across the Hooters ecosystem, we have a profound understanding of our customers and what it takes to not only meet, but consistently exceed their expectations,” said Neil Kiefer, a member of the buyer group and the current CEO of the original Hooters’ location in Clearwater, Florida.
Hooters said it expects to complete the deal and emerge from bankruptcy in three to four months. The company has lined up about $35 million in financing from its existing lender group to complete the bankruptcy transaction.
Casual dining restaurants have been hammered by rising costs in 2024, with well-known chains like TGI Fridays, Red Lobster, Bucca di Beppo, and Rubio’s Coastal Grill all filing for bankruptcy last year.
Restaurant prices have risen about 30% in the last 5 years, outpacing consumer prices overall, according to the Federal Reserve Bank of St. Louis.
This post appeared first on NBC NEWS
The House Foreign Affairs Committee (HFAC) is demanding that the United Nations not reappoint Special Rapporteur Francesca Albanese. Rep. Brian Mast, R-Fla., who chairs the committee, is leading the charge to oppose Albanese.
In a letter to U.N. Human Rights Council (UNHRC) President Jürg Lauber, the committee accuses Albanese of failing to uphold the council’s code of conduct. They also condemn Albanese for comments she made about Israel in the wake of Hamas’ Oct. 7 attacks.
‘Albanese unapologetically uses her position as a UN Special Rapporteur to purvey and attempt to legitimize antisemitic tropes, while serving as a Hamas apologist,’ the committee wrote in its letter. ‘In her malicious fixation, she has even called for Israel to be removed from the United Nations while likening Israel to apartheid South Africa.’
The committee not only criticized Albanese but also slammed the UNHRC, saying its leaders ‘allowed antisemitism and anti-Americanism to thrive within, with a seeming unwillingness to hold the most egregious violators of human rights to account.’
‘Francesca Albanese is an unabashed anti-Israel activist who has consistently done the bidding of Hamas terrorists responsible for the heinous October 7th attacks. Her appointment is a disgrace to the U.N. It’s time for the U.N. to claw back the integrity and accountability it has surrendered,’ Mast told Fox News Digital.
U.N. Watch Executive Director Hillel Neuer lauded the ‘much needed’ action from Congress. In a statement to Fox News Digital, Neuer said that Albanese’s reappointment would be ‘unlawful’ and called for ‘consequences’ from the U.S. if she visits the country.
‘Francesca Albanese openly supports Hamas, spreads antisemitic tropes, and tramples the U.N.’s own Code of Conduct. Under the U.N.’s own rules, the president of the Human Rights Council is now duty-bound to convey to the plenary this and other substantial objections that have been submitted, and for the delegates to formally consider Albanese’s many violations. And yet every indication is that the 47-member body — with the EU’s complicity — is instead barreling ahead with Albanese’s reappointment,’ Neuer said in a statement to Fox News Digital.
Albanese, who was appointed special rapporteur in 2022, has been condemned by the governments of multiple countries and faced accusations of antisemitism. Her response to French President Emmanuel Macron calling the Oct. 7 attacks ‘the largest antisemitic massacre of our century’ sparked backlash from France, the U.S. and Germany.
The U.S. slammed Albanese for her ‘history of using antisemitic tropes,’ and said her comments were ‘justifying, dismissing [and] denying the antisemitic undertones of Hamas’ October 7 attack are unacceptable [and] antisemitic.’
The French Mission to the U.N. condemned Albanese’s response in a post on X. According to the Anti-Defamation League’s (ADL) translation, the post read: ‘The October 7 massacre is the largest antisemitic massacre of the 21st century. To deny it is wrong. To seem to justify it, by bringing in the name of the United Nations, is a shame.’ This was just a few months after the mission condemned her ‘hate speech and antisemitism.’
Germany retweeted France’s statement and said, ‘To justify the horrific terror attacks of 7/10 & deny their antisemitic nature is appalling. Making such statements in a UN capacity is a disgrace and goes against everything the United Nations stands for.’
The Office of the High Commissioner for Human Rights did not immediately respond to Fox News Digital’s request for comment.
This post appeared first on FOX NEWS
Celsius Holdings Inc (NASDAQ: CELH) rallied as much as 10% on Monday after a Truist analyst said the company’s focus on women as a target market could unlock significant upside in its share price.
In a research note, the investment firm upgraded CELH this morning to “buy”.
Its analyst Bill Chappell upwardly revised his price target on Celsius stock today to $45 that indicates potential upside of another 25% from current levels, which is exciting given it has already more than doubled since mid-February.
Chappell is bullish on CELH’s Alani acquisition
Truist continues to see significant further upside in Celsius shares particularly because the Nasdaq listed firm announced plans of acquiring Alani Nu brand for $1.65 billion last month.
Alani had been cutting into Celsius sales that have declined about 6% in recent months.
But that overhang will effectively be removed from CELH once it completes its cash and stock agreement with Alani, its analyst Bill Chappell told investors in a note today.
Together, Celsius and Alani currently own about 16% of the US energy drinks space.
However, their combined share sits at a much higher, close to 50%, in the women segment of that market.
Note that Celsius stock does not currently pay a dividend, though.
Celsius to expand its footprint in women segment
Chappell expects the Alani acquisition to help Celsius dominate the women segment of the US energy drinks market.
This could prove lucrative for CELH as women are increasingly accounting for a bigger chunk of that category’s sales.
At writing, they drive less than 30% of the energy drink sales globally.
However, the Truist analyst is convinced that women will generate a well over 100% growth in that market in the future.
Meanwhile, rivals like Red Bull and Monster Beverage “have been built to focus on male consumers”, leaving this whole, fast-growing segment entirely for Celsius to own, Chappell added.
Should you buy Celsius stock today?
Celsius stock is now trading at a year-to-date high but Truist continues to recommend loading up on it for the strength of the company’s financials as well.
In February, the energy drinks giant reported 14 cents a share of earnings on a record revenue of about $332 million for its fiscal Q4.
Analysts, in comparison, were at 11 cents per share and $326 million, respectively.
At the time, Jarrod Langhans, CELH’s chief of finance told investors:
We’re pleased that our strategic initiatives are driving long-term share gains and strong retail sales growth.
We believe our capital allocation strategy is fully aligned with our vision to be a high-growth leader and deliver the greatest value to our consumers and shareholders.
The rest of the Wall Street also recommends buying Celsius stock with the mean target of $40 indicating about a 10% upside from here.
The post Celsius bets on women consumers—will its stock soar? appeared first on Invezz
Quimbaya Gold Inc. (CSE: QIM) (OTCQB: QIMGF) (FSE: K05) (‘Quimbaya Gold’ or the ‘Company’) is pleased to announce that shareholders voted to approve all items of business put forth to shareholders at the Company’s Annual General and Special Meeting (‘AGSM’) held on March 28, 2025, including the election of directors, fixing the number of directors, appointment of the Company’s auditor, approval of the equity incentive plan, and the continuation of the Company under the British Columbia Business Corporations Act.
The board of directors and the Company would like to thank Mr. Bayona, who did not run for re-election, for his service to the Company and would like to wish him well in his future endeavors.
Additionally, at the AGSM, Sebastian Wahl was elected as new independent director of the Company. Sebastian Wahl brings over 15 years of experience in the mining industry, specializing in precious metals trading and corporate development. As a co-founder and former Vice President of Corporate Development at Silver X Mining Corp., he played a pivotal role in consolidating assets and advancing projects in South America. Mr. Wahl holds a B.Sc. in Business Administration from the Graduate School of Business Administration in Zurich and a Financial Modelling certification from the Corporate Finance Institute. Fluent in Spanish, he possesses extensive expertise in South American mining operations and capital markets.
Mr. Alexandre P. Boivin, President & CEO stated, ‘We are excited to bring Sebastian on as an independent board member. His strong experience in South America and European connections will complement the Company as we strive to become an established player in the Colombian mining exploration space.’
About Quimbaya
Quimbaya aims to discover gold resources through exploration and acquisition of mining properties in the prolific mining districts of Colombia. Managed by an experienced team in the mining sector, Quimbaya is focused on three projects in the regions of Segovia (Tahami Project), Puerto Berrio (Berrio Project), and Abejorral (Maitamac Project), all located in Antioquia Province, Colombia.
Contact Information
Alexandre P. Boivin, President and CEO apboivin@quimbayagold.com
Jason Frame, Manager of Communications jason.frame@quimbayagold.com
Quimbaya Gold Inc.
Follow on X @quimbayagoldinc
Follow on LinkedIn @quimbayagold
Follow on Instagram @quimbayagoldinc
Follow on Facebook @quimbayagoldinc
Cautionary Statements
Certain statements contained in this press release constitute ‘forward-looking information’ as that term is defined in applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as ‘intends’, ‘expects’ or ‘anticipates’, or variations of such words and phrases or statements that certain actions, events or results ‘may’, ‘could’, ‘should’, ‘would’ or ‘occur’. Forward-looking information by its nature is based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Quimbaya to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Although Quimbaya’s management believes that the assumptions made and the expectations represented by such information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate. Furthermore, should one or more of the risks, uncertainties or other factors materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in forward-looking statements or information. Readers are cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Quimbaya as of the date of this news release and, accordingly, is subject to change after such date. Except as required by law, Quimbaya does not expect to update forward-looking statements and information continually as conditions change.
Neither the Canadian Securities Exchange nor its regulation services provider accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/246745
News Provided by Newsfile via QuoteMedia
This post appeared first on investingnews.com